Elizabeth McKenna(@ElizSMcKenna) 's Twitter Profileg
Elizabeth McKenna

@ElizSMcKenna

Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Views/likes/RTs are my own. She/her

ID:24753832

linkhttps://aacrjournals.org/cancerdiscovery calendar_today16-03-2009 19:42:02

11,8K Tweets

15,0K Followers

5,1K Following

Follow People
FDA Oncology(@FDAOncology) 's Twitter Profile Photo

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - via Cancer Discovery. 1st author Joshua M. Donaldson, last author Richard Pazdur Rick Pazdur.
aacrjournals.org/cancerdiscoverā€¦

account_circle
Cancer Discovery(@CD_AACR) 's Twitter Profile Photo

From the December issueā€”
Gain-of-Function Mutation Induces via BRD4-dependent Csf-1 expression, by Gizem Efe, Anil K. Rustgi et al.
bit.ly/3TxHIbJ
@ColumbiaCancer

From the December issueā€” #p53 Gain-of-Function Mutation Induces #Metastasis via BRD4-dependent Csf-1 expression, by Gizem Efe, @ARustgi et al. bit.ly/3TxHIbJ @ColumbiaCancer
account_circle
Norbert Kraut(@norbertkraut1) 's Twitter Profile Photo

2023 has been a year with major advances in A must-read in Cancer Discovery
Precision Oncology: 2023 in Review aacrjournals.org/cancerdiscoverā€¦

account_circle
Cancer Discovery(@CD_AACR) 's Twitter Profile Photo

From the December issueā€”
Formate Supplementation Enhances Anti-Tumor CD8+ Fitness and Efficacy of PD-1 Blockade, by Jared Rowe, Ilaria Elia, Marcia Haigis, Arlene Sharpe et al.
bit.ly/3NBXqPq
Dana-Farber Harvard Medical School

From the December issueā€” Formate Supplementation Enhances Anti-Tumor CD8+ #TCell Fitness and Efficacy of PD-1 Blockade, by Jared Rowe, @ilaria_elia, @HaigisLab, Arlene Sharpe et al. bit.ly/3NBXqPq @DanaFarber @harvardmed #metabolism #immunotherapy
account_circle
Xin (Cindy) Sun(@Cindy_JExpMed) 's Twitter Profile Photo

One-carbon (1C) in for this week's JExpMed

Marcia Haigis @ Arlene Sharpe and colleagues report that 'Formate Supplementation Enhances Antitumor CD8+T-cell Fitness and Efficacy of PD-1 Blockade'šŸŽÆCancer Discovery
doi.org/10.1158/2159-8ā€¦

account_circle
Cancer Discovery(@CD_AACR) 's Twitter Profile Photo

From the December issueā€”
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multi-Cancer Biomarker, by @mTORC3, Connie Wu, David Walt, Kathleen Helen Burns et al.
bit.ly/478IMWX
Mass General Brigham UMLifeSciences Dana-Farber

From the December issueā€” Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multi-Cancer Biomarker, by @mTORC3, Connie Wu, David Walt, @KathleenHBurns et al. bit.ly/478IMWX @MassGenBrigham @UMLifeSciences @DanaFarber #LiquidBiopsy #TransposableElement
account_circle
FDA Oncology(@FDAOncology) 's Twitter Profile Photo

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development - via Cancer Discovery. 1st author Joshua M. Donaldson, last author Richard Pazdur Rick Pazdur.
aacrjournals.org/cancerdiscoverā€¦

account_circle
Cancer Discovery(@CD_AACR) 's Twitter Profile Photo

In Focusā€”
Highlights of FDA Oncology Approvals in 2023: Bispecific Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the U.S. FDA Center for Drug Evaluation and Research and Oncology Center of Excellence.
bit.ly/3v6hvqE

In Focusā€” Highlights of FDA Oncology Approvals in 2023: Bispecific #TCell Engagers, Pediatric Indications, & Inclusive Drug Development, by Joshua M. Donaldson et al. at the @US_FDA Center for Drug Evaluation and Research and Oncology Center of Excellence. bit.ly/3v6hvqE
account_circle
Debyani Chakravarty, PhD šŸ‡ŗšŸ‡¦(@CDebyaniPhD) 's Twitter Profile Photo

2023 in review people! Published in Cancer Discovery & and very soon a table itemizing the key developments to be released on the OncoKBā„¢ websiteā€¦stay tuned for our last website release for 2023 - it will be a BIG one (HUGE in fact)!

account_circle